Prognostic factors in patients with metastatic RCC receiving anti-VEGF therapy
This article has no abstract so we have provided the first paragraph of the full text.
Current treatment algorithms for patients with advanced renal cell carcinoma (RCC) were developed on the basis of patients treated with cytokines or chemotherapy; however, most patients now receive VEGF-targeted therapies. Choueiri et al. have identified five factors that can predict progression-free survival (PFS) in patients treated with anti-VEGF agents and used these factors to develop a prognostic model.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.